110 related articles for article (PubMed ID: 30773105)
1. The utility of a telemedicine platform to monitor adherence and adverse effects of tyrosine kinase inhibitors.
Copeland AC; Foster MC; Muluneh B; Xenakis JG; Ivanova A; Frankfurt O; Clayton M; Black A; Rapchak B; Wehbie RS
Leuk Lymphoma; 2019 Jul; 60(7):1842-1844. PubMed ID: 30773105
[No Abstract] [Full Text] [Related]
2. Identifying Tyrosine Kinase Inhibitor Nonadherence in Chronic Myeloid Leukemia: Subanalysis of TAKE-IT Pilot Study.
Leader A; Gafter-Gvili A; Benyamini N; Dreyer J; Calvarysky B; Amitai A; Yarchovsky-Dolberg O; Sharf G; Tousset E; Caspi O; Ellis M; Levi I; Raanani P; De Geest S
Clin Lymphoma Myeloma Leuk; 2018 Sep; 18(9):e351-e362. PubMed ID: 30122203
[TBL] [Abstract][Full Text] [Related]
3. Effect of Adherence-enhancing Interventions on Adherence to Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia (TAKE-IT): A Quasi-experimental Pre-Post Intervention Multicenter Pilot Study.
Leader A; Benyamini N; Gafter-Gvili A; Dreyer J; Calvarysky B; Amitai A; Yarchovsky-Dolberg O; Sharf G; Tousset E; Caspi O; Ellis M; Levi I; De Geest S; Raanani P
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e449-e461. PubMed ID: 30030034
[TBL] [Abstract][Full Text] [Related]
4. Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Breccia M; Colafigli G; Molica M; Alimena G
Expert Opin Drug Saf; 2016; 15(4):525-33. PubMed ID: 26799331
[TBL] [Abstract][Full Text] [Related]
5. Targeted cancer therapy: from bench to bedside to patient.
Gellad WF
J Clin Oncol; 2014 Feb; 32(4):268-70. PubMed ID: 24366939
[No Abstract] [Full Text] [Related]
6. Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events.
Carneiro BA; Kaplan JB; Giles FJ
Expert Rev Hematol; 2015 Aug; 8(4):457-79. PubMed ID: 25938861
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
8. Tyrosine kinase inhibitors for chronic myelogenous leukemia.
Defuentes G; Bladé JS; Berets O
N Engl J Med; 2007 Oct; 357(15):1556-7; author reply 1557-8. PubMed ID: 17928609
[No Abstract] [Full Text] [Related]
9. Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase.
Guérin A; Chen L; Dea K; Wu EQ; Goldberg SL
Curr Med Res Opin; 2014 Jul; 30(7):1345-52. PubMed ID: 24640967
[TBL] [Abstract][Full Text] [Related]
10. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
Jabbour E; Cortes J; Kantarjian H
Curr Opin Oncol; 2006 Nov; 18(6):578-83. PubMed ID: 16988578
[TBL] [Abstract][Full Text] [Related]
11. Adherence to treatment is a complex and multifaceted issue that can substantially alter the outcome of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Breccia M; Efficace F; Alimena G
Leuk Res; 2012 Jul; 36(7):804-5. PubMed ID: 22459331
[No Abstract] [Full Text] [Related]
12. Front-line use of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: Practice considerations.
Reff MJ; Shillingburg A; Shah B; Elder C; Prescott H; Kennerly-Shah J
J Oncol Pharm Pract; 2020 Jan; 26(1):156-174. PubMed ID: 31354102
[TBL] [Abstract][Full Text] [Related]
13. Adherence to tyrosine kinase inhibitor therapy for chronic myeloid leukemia: a Brazilian single-center cohort.
de Almeida MH; Pagnano KB; Vigorito AC; Lorand-Metze I; de Souza CA
Acta Haematol; 2013; 130(1):16-22. PubMed ID: 23363706
[TBL] [Abstract][Full Text] [Related]
14. Skeletal muscle toxicity associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
Janssen L; Frambach SJCM; Allard NAE; Hopman MTE; Schirris TJJ; Voermans NC; Rodenburg RJ; Blijlevens NMA; Timmers S
Leukemia; 2019 Aug; 33(8):2116-2120. PubMed ID: 30872782
[No Abstract] [Full Text] [Related]
15. Extranodal marginal zone lymphoma arising in a patient with chronic myelogenous leukemia on long-term tyrosine kinase inhibitors.
Xu X; Hassan A
Leuk Lymphoma; 2014 Mar; 55(3):715-7. PubMed ID: 23741976
[No Abstract] [Full Text] [Related]
16. Severe periorbital edema secondary to imatinib mesylate for chronic myelogenous leukemia.
Larson JS; Bergstrom LK; Cameron JD; Erickson LA; Grimm TE
Arch Ophthalmol; 2007 Jul; 125(7):985-6. PubMed ID: 17620589
[No Abstract] [Full Text] [Related]
17. Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia.
Winn AN; Keating NL; Dusetzina SB
J Clin Oncol; 2016 Dec; 34(36):4323-4328. PubMed ID: 27998234
[TBL] [Abstract][Full Text] [Related]
18. Experiences of living with chronic myeloid leukaemia and adhering to tyrosine kinase inhibitors: A thematic synthesis of qualitative studies.
Hewison A; Atkin K; McCaughan D; Roman E; Smith A; Smith G; Howell D
Eur J Oncol Nurs; 2020 Apr; 45():101730. PubMed ID: 32169687
[TBL] [Abstract][Full Text] [Related]
19. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
[TBL] [Abstract][Full Text] [Related]
20. Severe dyspnoea in a patient with chronic myelogenous leukaemia on a tyrosine kinase inhibitor.
Ustun C; Randall N; Podgaetz E; Amin K; Dincer HE
Thorax; 2015 Jul; 70(7):701-4. PubMed ID: 25935168
[No Abstract] [Full Text] [Related]
[Next] [New Search]
